GOLD
SILVER
DNA is in our blood Natera™ is a global leader in cell-free DNA (cfDNA) testing, dedicated to oncology, women’s health, and organ health. We aim to make personalized genetic testing and diagnostics part of the standard of care to protect health and inform earlier, more targeted interventions that help lead to longer, healthier lives. Signatera™ is a personalized, tumor-informed assay optimized to detect circulating tumor DNA (ctDNA) for molecular residual disease (MRD) assessment, treatment response monitoring, and early recurrence monitoring.
Axogen has over 15 years of experience as a leader in surgical solutions for peripheral nerve repair. Our solutions are used primarily by hand surgeons, reconstructive plastic surgeons, and oral and maxillofacial surgeons in a wide variety of nerve repair surgeries across the body. Our mission is to restore health and improve quality of life by making restoration of peripheral nerve function an expected standard of care.
INNOVATION LAB: 4 technique handling stations where attendees can rotate through to learn and practice nerve repair techniques
BD is one of the world’s largest pure-play medical technology companies with a Purpose of advancing the world of health™ by driving innovation across medical essentials, connected care, biopharma systems and interventional. The company supports those on the frontlines of healthcare by developing transformative technologies, services and solutions that optimize clinical operations and improve care for patients. Operating across the globe, with more than 60,000 employees, BD delivers billions of products annually that have a positive impact on global healthcare. By working in close collaboration with customers, BD can help enhance outcomes, lower costs, increase clinical efficiency, improve safety and expand access to healthcare.
HistoSonics has developed a non-invasive, sonic beam therapy platform that uses histotripsy, which is capable of destroying targeted liver tumors at a sub-cellular level. Histotripsy is a novel form of focused ultrasound that uses high amplitude, very short pulses to create a “bubble cloud” that is designed to mechanically destroy and liquefy targeted liver tumors.
Merit Oncology is dedicated to easing the burden on cancer patients and their families by delivering first-in-class radar localization treatment with SCOUT MD.
INNOVATION LAB: Merit Oncology will showcase our newest technology, SCOUT MD.
At Johnson & Johnson we believe good health is the foundation of vibrant lives, thriving communities and forward progress. We strive to not only innovate across MedTech and Innovative Medicine but to improve access and affordability to lifesaving and life-enhancing treatments and medical solutions around the world. We are able to do this because for more than 80 years, our commitment to helping people has been built into our mission statement and purpose.
The values that guide our decision-making are spelled out in Our Credo. Put simply, Our Credo challenges us to put the needs and well-being of the people we serve first.
Our Credo is more than just a moral compass. We believe it’s a recipe for business success. The fact that Johnson & Johnson is one of only a handful of companies that has flourished through more than a century of change is proof of that.
We blend heart, science and ingenuity to profoundly impact health for humanity.
From the town of Isafjordur in northwest Iceland, Kerecis develops, manufactures, and sells patented fish-skin soft tissue regeneration products that have regulatory approval in the United States, Europe and several other jurisdictions.
The intact Kerecis fish skin is being used to treat wounds, burns and other complex acute and chronic wounds including diabetic, venous, trauma, and surgical wounds. Thousands of patients of all incomes, cultures and races have benefited from treatment with Kerecis.
Our fish skin comes from wild Atlantic cod, caught from a sustainable fish stock in pristine Icelandic waters and processed using renewable energy.
BRONZE
As a leading provider of innovative technologies for the treatment of Atrial Fibrillation (Afib) and related conditions, electrophysiologists, cardiothoracic and thoracic surgeons around the globe count on AtriCure to deliver best-in-class solutions that can treat even the most complex cases. Our Isolator® Synergy™ Ablation System is the first medical device to receive FDA approval for the treatment of persistent Afib. Our AtriClip® Left Atrial Appendage Exclusion System products are the most widely sold LAA management devices worldwide. Our Hybrid AF™ Therapy is a minimally invasive procedure that provides a lasting solution for long-standing persistent Afib patients. Our cryoICE cryoSPHERE®+ and cryoSPHERE MAX™ probes are cleared for temporary ablation of peripheral nerves to block pain, providing pain relief in cardiac and thoracic procedures. We invest in innovation, clinical science, and education to focus on improving lives for our patients worldwide.